
22/09/2025
Chronic myeloid leukaemia (CML) is a rare type of blood cancer that affects the bone marrow and blood, gradually interfering with the body’s ability to produce healthy cells. For people living with CML, every treatment milestone has been a chance to reclaim hope. What began as a mystery in the lab decades ago grew into targeted therapies that transformed outcomes worldwide.
When patients could no longer respond to earlier treatments, continued innovation brought new therapies and renewed possibilities for care. These advancements were not only scientific achievements but also lifelines for patients and families navigating uncertainty.
At Novartis, we have remained committed to pushing the boundaries of science to reimagine medicine for CML patients. Every trial, every therapy, and every insight reflects a shared purpose: to improve the lives of people living with CML and other rare diseases.